Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) to Post FY2025 Earnings of $1.50 Per Share, Leerink Partnrs Forecasts

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) – Stock analysts at Leerink Partnrs upped their FY2025 earnings per share (EPS) estimates for Intra-Cellular Therapies in a report issued on Tuesday, May 7th. Leerink Partnrs analyst M. Goodman now expects that the biopharmaceutical company will earn $1.50 per share for the year, up from their previous forecast of $1.35. The consensus estimate for Intra-Cellular Therapies’ current full-year earnings is ($0.59) per share. Leerink Partnrs also issued estimates for Intra-Cellular Therapies’ FY2026 earnings at $3.15 EPS and FY2028 earnings at $6.80 EPS.

Intra-Cellular Therapies (NASDAQ:ITCI) last released its quarterly earnings results on Tuesday, May 7th. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.15. The firm had revenue of $144.90 million during the quarter, compared to analysts’ expectations of $141.41 million. Intra-Cellular Therapies had a negative return on equity of 23.02% and a negative net margin of 30.08%. Intra-Cellular Therapies’s quarterly revenue was up 52.0% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.46) EPS.

ITCI has been the topic of a number of other research reports. Bank of America boosted their price objective on shares of Intra-Cellular Therapies from $82.00 to $91.00 and gave the stock a “buy” rating in a report on Wednesday, April 17th. The Goldman Sachs Group boosted their price target on Intra-Cellular Therapies from $67.00 to $77.00 and gave the stock a “neutral” rating in a research note on Wednesday, April 17th. Cantor Fitzgerald restated an “overweight” rating and set a $120.00 price objective on shares of Intra-Cellular Therapies in a research note on Wednesday, April 24th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $86.00 target price on shares of Intra-Cellular Therapies in a research report on Wednesday, April 3rd. Finally, TD Cowen raised their price target on shares of Intra-Cellular Therapies from $80.00 to $90.00 and gave the stock a “buy” rating in a research report on Wednesday, April 17th. Two equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $90.17.

Intra-Cellular Therapies Trading Down 2.1 %

Shares of ITCI stock opened at $65.56 on Thursday. The firm has a fifty day simple moving average of $68.95 and a 200-day simple moving average of $65.86. The company has a market capitalization of $6.35 billion, a PE ratio of -44.90 and a beta of 1.01. Intra-Cellular Therapies has a twelve month low of $45.50 and a twelve month high of $84.89.

Insider Activity

In related news, CEO Sharon Mates sold 20,565 shares of the stock in a transaction dated Monday, March 11th. The shares were sold at an average price of $65.21, for a total transaction of $1,341,043.65. Following the sale, the chief executive officer now owns 1,050,309 shares in the company, valued at $68,490,649.89. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In related news, CEO Sharon Mates sold 20,565 shares of the company’s stock in a transaction on Monday, March 11th. The stock was sold at an average price of $65.21, for a total transaction of $1,341,043.65. Following the completion of the transaction, the chief executive officer now directly owns 1,050,309 shares in the company, valued at approximately $68,490,649.89. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, EVP Michael Halstead sold 7,907 shares of the stock in a transaction on Monday, February 26th. The stock was sold at an average price of $69.53, for a total value of $549,773.71. Following the completion of the sale, the executive vice president now directly owns 29,700 shares in the company, valued at $2,065,041. The disclosure for this sale can be found here. In the last three months, insiders sold 168,487 shares of company stock valued at $11,364,950. Company insiders own 3.40% of the company’s stock.

Institutional Trading of Intra-Cellular Therapies

Several hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. increased its stake in shares of Intra-Cellular Therapies by 6.5% in the fourth quarter. Vanguard Group Inc. now owns 9,094,302 shares of the biopharmaceutical company’s stock valued at $651,334,000 after purchasing an additional 554,577 shares during the period. Wasatch Advisors LP grew its holdings in Intra-Cellular Therapies by 6.3% in the 1st quarter. Wasatch Advisors LP now owns 3,854,747 shares of the biopharmaceutical company’s stock worth $266,748,000 after buying an additional 227,439 shares in the last quarter. Avoro Capital Advisors LLC acquired a new stake in Intra-Cellular Therapies in the 4th quarter valued at approximately $161,543,000. JPMorgan Chase & Co. raised its stake in Intra-Cellular Therapies by 4.4% during the 3rd quarter. JPMorgan Chase & Co. now owns 2,063,802 shares of the biopharmaceutical company’s stock valued at $107,503,000 after acquiring an additional 86,388 shares in the last quarter. Finally, Wellington Management Group LLP boosted its position in Intra-Cellular Therapies by 6.7% during the 3rd quarter. Wellington Management Group LLP now owns 1,815,954 shares of the biopharmaceutical company’s stock worth $94,593,000 after acquiring an additional 114,370 shares during the period. 92.33% of the stock is currently owned by institutional investors.

Intra-Cellular Therapies Company Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.